Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors

Circulation

Volumn 109, Issue 4, 2004, Pages 513-519

  White, Stephen J ^a,b   Nicklin, Stuart A ^b   Büning, Hildegard ^c   Brosnan, M Julia ^b   Leike, Kristen ^c   Papadakis, Emmanuel D ^a   Hallek, Michael ^c,d,e   Baker, Andrew H ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Gesellshaft fur Strahelforschung   (Germany)

Author keywords

Endothelium; Gene therapy; Peptides; Viruses

Indexed keywords

ADENOVIRUS VECTOR;

ARTICLE; BINDING SITE; CARDIOVASCULAR DISEASE; CAVA VEIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ANALYSIS; HEPARINIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER PERFUSION; METABOLIC CLEARANCE RATE; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE; TRANSGENE; VASCULAR ENDOTHELIUM; VASCULAR TISSUE; VIRAL GENE THERAPY; VIRUS CAPSID;

ANIMALS; CELLS, CULTURED; DEPENDOVIRUS; ENDOTHELIUM, VASCULAR; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; PEPTIDE LIBRARY; PEPTIDES; TRANSDUCTION, GENETIC;

EID: 0842264162     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000109697.68832.5D     Document Type: Article

References (25)

1. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 1999;354:1493-1498.
2. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002;105:1291-1297.
3. Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest. 1998;102:410-437.
4. Arap W, Kolonin MG, Trepel M, et al. Steps towards mapping the human vasculature by phage display. Nat Med. 2002;8:121-127.
5. Koeberl DD, Alexander IE, Halbert CL, et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA. 1997;94:1426-1431.
6. Huard J, Lochmuller H, Acsadi G, et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 1995;2:107-115.
7. Ohashi K, Park F, Kay MA. Role of hepatocyte derived hyperplasia in lentivirus-mediated liver transduction in vivo. Hum Gene Ther. 2002;13:653-663.
8. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998;72:1438-1445.
9. Qing K, Mah C, Hansen J, et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med. 1999;5:71-77.
10. Summerford C, Bartlett JS, Samulski R-J. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med. 1999;5:78-82.
11. Nicklin SA, Buening H, Dishart KL, et al. Efficient and selective AAV-2 mediated gene transfer directed to human vascular endothelial cells. Mol Ther. 2001;4:174-181.
12. Nicklin SA, Baker AH. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr Gene Ther. 2002;2:273-293.
13. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med. 1999;5:1052-1056.
14. Nicklin SA, Reynolds PN, Brosnan MJ, et al. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension. 2001;38:65-70.
15. O'Connell KA, Edidin M. A mouse endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J Immunol. 1990;144:521-525.
16. Nicklin SA, White SJ, Watkins SJ, et al. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation. 2000;102:231-237.
17. Seisenberger G, Ried MU, Endreß T, et al. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science. 2001;294:1929-1932.
18. Pajusola K, Gruchala M, Joch H, et al. Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Virol. 2002;76:11530-11540.
19. Nathwani AC, Davidoff A, Hanawa H, et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood. 2001;97:1258-1265.
20. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A. 2002;99:10405-10410.
21. Hansen J, Qing K, Kwon H-J, et al. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol. 2000;74:992-996.
22. Hansen J, Qing K, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J Virol. 2001;75:4080-4090.
23. Duan D, Yue Y, Yan Z, et al. Endosomal processing limits gene transfer to polarised airway epithelia by adeno-associated virus. J Clin Invest. 2000;105:1573-1587.
24. Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther. 2003;7:515-525.
25. v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15:542-546.